As lorcaserin is the first weight-loss drug proven to have cardiovascular safety60 and olanzapine worsens hyperlipidemia and aortic inflammation, our finding that (R)-DOI possesses vascular protective effects independent of weight-loss suggests that biased signaling at 5-HT2 receptors confers different therapeutic properties in vascular tissues. Here, HTR2A is linked to hyperlipidemia.